PDF herunterladen
Thromb Haemost 2019; 119(08): 1332-1346
DOI: 10.1055/s-0039-1692174
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension

Sebastian Kölmel
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
,
Lukas Hobohm
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
2   Cardiology I, Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
,
Anja Käberich
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
2   Cardiology I, Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
,
Valentin J. Krieg
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
,
Magdalena L. Bochenek
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
2   Cardiology I, Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
3   DZHK (German Centre for Cardiovascular Research), partner site Rhine-Main, Germany
,
Philip Wenzel
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
2   Cardiology I, Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
3   DZHK (German Centre for Cardiovascular Research), partner site Rhine-Main, Germany
,
Christoph B. Wiedenroth
4   Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
,
Christoph Liebetrau
3   DZHK (German Centre for Cardiovascular Research), partner site Rhine-Main, Germany
5   Department of Cardiology, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
6   Division of Cardiology, Department of Internal Medicine I, University of Giessen, Giessen, Germany
,
Gerd Hasenfuß
7   Clinic of Cardiology and Pneumology, Heart Centre, University Medicine Göttingen, Göttingen, Germany
8   DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Germany
,
Eckhard Mayer
4   Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
,
Stavros V. Konstantinides
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
9   Department of Cardiology, Democritus University of Thrace, Alexandroupoli, Greece
,
Katrin Schäfer
2   Cardiology I, Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
3   DZHK (German Centre for Cardiovascular Research), partner site Rhine-Main, Germany
,
Stefan Guth   *
4   Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
,
Mareike Lankeit   *
1   Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
7   Clinic of Cardiology and Pneumology, Heart Centre, University Medicine Göttingen, Göttingen, Germany
10   Department of Internal Medicine and Cardiology, Campus Virchow Klinikum (CVK), Charité–University Medicine, Berlin, Germany
11   DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany
› Institutsangaben Funding This study was supported by the German Federal Ministry of Education and Research (BMBF 01EO1003 and BMBF 01EO1503). The authors are responsible for the contents of this publication. The work is part of the medical doctoral thesis of Sebastian Kölmel and his work was supported by a Doctoral Candidate Fellowship 2016 of the Center for Thrombosis and Hemostasis (CTH) of the University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Weitere Informationen

Publikationsverlauf

11. Dezember 2018

11. April 2019

Publikationsdatum:
10. Juni 2019 (online)

    Lizenzen und Reprints

Abstract

Background Inflammation and incomplete thrombus resolution leading to obstructive fibrotic remodelling are considered critical mechanisms for the development of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE). Osteopontin (OPN) is involved in a variety of biological processes including inflammation and tissue fibrosis.

Methods OPN plasma concentrations were measured in 70 CTEPH and 119 PE patients. Tissue material from 6 CTEPH patients removed during pulmonary endarterectomy and murine venous thrombi induced by subtotal ligation of the inferior vena cava in C57BL/6 mice were analysed by (immuno)histochemistry.

Results CTEPH patients had higher OPN plasma concentrations (median, 106.9 [interquartile range, 75.6–155.9]) compared to PE patients (90.4 [53.3–123.9] ng/mL, p = 0.001). OPN- and matrix metalloproteinase (MMP)-9-positive cells were predominantly present in myofibroblast-rich and profibrotic areas of CTEPH tissue material. Early stages of murine thrombus resolution were characterised by high numbers of OPN- and MMP-2-positive cells while OPN was almost absent in fresh thrombi of CTEPH tissue material. PE patients with OPN plasma concentrations of < 55 ng/mL had a 15.2-fold (95% confidence interval, 1.7–135.5, p = 0.015) increased risk for a diagnosis of CTEPH during follow-up.

Conclusion The results of the present observational translational study point to a possible involvement of OPN in the pathogenesis of CTEPH by affecting early inflammatory and late fibrotic processes.

Keywords

thrombus resolution - fibrosis - inflammation - osteopontin - chronic thromboembolic pulmonary hypertension

* The authors contributed equally and share last authorship.


Supplementary Material

 

  • References

  • 1 Franzén A, Heinegård D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985; 232 (03) 715-724
    CrossrefPubMedGoogle Scholar
  • 2 Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995; 57 (04) 680-690
    CrossrefPubMedGoogle Scholar
  • 3 Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001; 280 (02) 460-465
    CrossrefPubMedGoogle Scholar
  • 4 Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal 2009; 3 (3-4): 311-322
    CrossrefPubMedGoogle Scholar
  • 5 Morimoto J, Kon S, Matsui Y, Uede T. Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 2010; 11 (04) 494-505
    CrossrefPubMedGoogle Scholar
  • 6 Rosenberg M, Meyer FJ, Gruenig E. , et al. Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH). Int J Cardiol 2012; 155 (03) 504-505
    CrossrefPubMedGoogle Scholar
  • 7 O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000; 81 (06) 373-390
    PubMedGoogle Scholar
  • 8 Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994; 145 (06) 1450-1462
    PubMedGoogle Scholar
  • 9 Rosenberg M, Zugck C, Nelles M. , et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008; 1 (01) 43-49
    CrossrefPubMedGoogle Scholar
  • 10 Delcroix M, Lang I, Pepke-Zaba J. , et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133 (09) 859-871
    CrossrefPubMedGoogle Scholar
  • 11 Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013; 41 (02) 462-468
    CrossrefPubMedGoogle Scholar
  • 12 Quarck R, Wynants M, Verbeken E, Meyns B, Delcroix M. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J 2015; 46 (02) 431-443
    CrossrefPubMedGoogle Scholar
  • 13 Lankeit M, Krieg V, Hobohm L. , et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2017 ;S1053-2498(17)31877-6
    PubMedGoogle Scholar
  • 14 Lankeit M, Friesen D, Aschoff J. , et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31 (15) 1836-1844
    CrossrefPubMedGoogle Scholar
  • 15 Alias S, Redwan B, Panzenboeck A. , et al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014; 34 (04) 810-819
    CrossrefPubMedGoogle Scholar
  • 16 Bochenek ML, Rosinus NS, Lankeit M. , et al. From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2017; 117 (04) 769-783
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 17 Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89 (06) 2715-2721
    CrossrefPubMedGoogle Scholar
  • 18 Lorenzen JM, Nickel N, Krämer R. , et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest 2011; 139 (05) 1010-1017
    CrossrefPubMedGoogle Scholar
  • 19 Rosenberg M, Meyer FJ, Gruenig E. , et al. Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. Eur J Clin Invest 2012; 42 (09) 933-942
    CrossrefPubMedGoogle Scholar
  • 20 Singh M, Foster CR, Dalal S, Singh K. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol 2010; 48 (03) 538-543
    CrossrefPubMedGoogle Scholar
  • 21 Lorenzen JM, Hafer C, Faulhaber-Walter R. , et al. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2011; 26 (02) 531-537
    CrossrefPubMedGoogle Scholar
  • 22 Vaschetto R, Nicola S, Olivieri C. , et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med 2008; 34 (12) 2176-2184
    CrossrefPubMedGoogle Scholar
  • 23 Lorenzen J, Krämer R, Kliem V. , et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest 2010; 40 (04) 294-300
    CrossrefPubMedGoogle Scholar
  • 24 Kaleta B. The role of osteopontin in kidney diseases. Inflamm Res 2019; 68 (02) 93-102
    CrossrefPubMedGoogle Scholar
  • 25 Anwar A, Li M, Frid MG. , et al. Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2012; 303 (01) L1-L11
    CrossrefPubMedGoogle Scholar
  • 26 Burke DL, Frid MG, Kunrath CL. , et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 2009; 297 (02) L238-L250
    CrossrefPubMedGoogle Scholar
  • 27 Chen YF, Feng JA, Li P. , et al. Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling. J Appl Physiol (1985) 2006; 100 (02) 564-571
    CrossrefPubMedGoogle Scholar
  • 28 Altmann J, Sharma S, Lang IM. Advances in our understanding of mechanisms of venous thrombus resolution. Expert Rev Hematol 2016; 9 (01) 69-78
    CrossrefPubMedGoogle Scholar
  • 29 Lang IM, Dorfmüller P, Vonk Noordegraaf A. The pathobiology of chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc 2016; 13 (Suppl. 03) S215-S221
    CrossrefPubMedGoogle Scholar
  • 30 Evans CE, Grover SP, Humphries J. , et al. Antiangiogenic therapy inhibits venous thrombus resolution. Arterioscler Thromb Vasc Biol 2014; 34 (03) 565-570
    CrossrefPubMedGoogle Scholar
  • 31 Varma MR, Varga AJ, Knipp BS. , et al. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg 2003; 38 (05) 1090-1098
    CrossrefPubMedGoogle Scholar
  • 32 Kellermair J, Redwan B, Alias S. , et al. Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. Blood 2013; 122 (19) 3376-3384
    PubMedGoogle Scholar
  • 33 Henke PK, Varga A, De S. , et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol 2004; 24 (06) 1130-1137
    CrossrefPubMedGoogle Scholar
  • 34 Zheng W, Li R, Pan H. , et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 2009; 60 (07) 1957-1965
    CrossrefPubMedGoogle Scholar
  • 35 Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29 (06) 313-326
    CrossrefPubMedGoogle Scholar
  • 36 Deatrick KB, Eliason JL, Lynch EM. , et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 2005; 42 (01) 140-148
    CrossrefPubMedGoogle Scholar
  • 37 von Zur Mühlen C, Koeck T, Schiffer E. , et al. Urine proteome analysis as a discovery tool in patients with deep vein thrombosis and pulmonary embolism. Proteomics Clin Appl 2016; 10 (05) 574-584
    CrossrefPubMedGoogle Scholar
  • 38 Pola R, Ling LE, Silver M. , et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001; 7 (06) 706-711
    CrossrefPubMedGoogle Scholar
  • 39 Renault MA, Roncalli J, Tongers J. , et al. Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells. J Mol Cell Cardiol 2010; 49 (03) 490-498
    CrossrefPubMedGoogle Scholar
  • 40 Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010; 10 (01) 71-81
    CrossrefPubMedGoogle Scholar
  • 41 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340 (02) 115-126
    CrossrefPubMedGoogle Scholar
  • 42 Abdel-Azeez HA, Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal 2010; 24 (03) 201-206
    CrossrefPubMedGoogle Scholar
  • 43 Mercier O, Fadel E. Chronic thromboembolic pulmonary hypertension: animal models. Eur Respir J 2013; 41 (05) 1200-1206
    CrossrefPubMedGoogle Scholar
  • 44 Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A. , et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 2017; 49 (02) 1601792
    CrossrefPubMedGoogle Scholar